ReviewChest2020
Treatment of Community-Acquired Pneumonia in Immunocompromised Adults: A Consensus Statement Regarding Initial Strategies.
Registry-linked trialOpen access · bronzeAbstract readReviewConsensus Statement
In one paragraph
Review in Chest, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06755814 (Community-acquired Pneumonia in Immunosuppressed Adult Patients), which is not on this map. Cited by 134 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
134citing papers in PubMed, 1 pooled it
16.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Community-acquired Pneumonia in Immunosuppressed Adult Patients: Observational, Perspective Study, ItAlian ReGistry Of pNeumoniA in immUnocompromised paTients (ARGONAUT)
Who cites it
134 citing papers in PubMed, 1 synthesis or guideline pooled it, 227 citations in OpenAlex.
- Efficacy, effectiveness, and safety of herpes zoster vaccine in the immunocompetent and immunocompromised subjects: A systematic review and network meta-analysis.Frontiers in immunology · 2022Pooled it
- Epidemiology, risk factors and clinical outcome of community-acquired pneumonia in severely immunosuppressed patients: a comprehensive analysis from the multinational, prospective CAPNETZ Cohort.ERJ open research · 2026Article
- Metagenomic-based quantification of Pseudomonas aeruginosa burden links microbiome collapse to mortality in severe community-acquired pneumonia.Annals of clinical microbiology and antimicrobials · 2026Article
- Health system implementation of clinical decision support to optimize respiratory pathogen profile utilization.Journal of clinical microbiology · 2026Article
- Article
- Impact of corticosteroids on lung antibiotic resistance genes in patients with lower respiratory tract infections.Microbiology spectrum · 2026Article
- Harnessing next-generation microbial diagnostics to optimize infection management in immunocompromised hosts.Current opinion in infectious diseases · 2026Review
- Corticosteroids in immunocompromised ICU patients with pneumonia: risks, evidence, and clinical practice.Pneumonia (Nathan Qld.) · 2026Review
- Diagnostic discordance and differential diagnoses of community-acquired pneumonia in the emergency department.BMC emergency medicine · 2026Article
- Pneumonia after Solid Organ Transplantation.Seminars in respiratory and critical care medicine · 2026Review
- Characterization of multiple herpes viremia via next-generation sequencing in patients with lower respiratory tract infections: a retrospective cohort study.BMC infectious diseases · 2026Article
- Impact of glucocorticoid therapy on short- and long-term mortality in immunocompromised patients with community-acquired pneumonia in the ICU: a retrospective cohort study.BMC infectious diseases · 2026Article
- Evaluation of PSI, CURB-65, and CRB-65 as prognostic tools in hospitalized immunocompetent patients with pneumonia: real-world outcomes from internal medicine wards.Pneumonia (Nathan Qld.) · 2026Article
- The impact of the timing of mNGS-guided antibiotic adjustment on clinical outcomes in ICU patients with severe community-acquired pneumonia: a retrospective study.Annals of clinical microbiology and antimicrobials · 2026Article
- Prediction hospital mortality for critical illness lung cancer patients with pneumonia.BMC infectious diseases · 2026Article
- Evaluation of a lateral flow immunochromatographic assay for detecting cryptococcal antigens in bronchoalveolar lavage fluid from HIV-negative patients with pulmonary cryptococcosis.Microbiology spectrum · 2026Article
- Metagenomics next-generation sequencing of plasma combined with blood cells for improving the prognosis of early infection in patients with hematologic disorders: a real-world cohort study in northern China.Frontiers in molecular biosciences · 2026Article
- Diagnostic Performance of Bronchoalveolar Lavage Fluid Metagenomic Next‑generation Sequencing versus Conventional Microbiological Tests in Immunocompromised and Immunocompetent Patients with Pulmonary Infection.Infection and drug resistance · 2026Article
- Microbiological replacement associated with recurrent pneumonia during chemotherapy for Hodgkin lymphoma: a case report.Access microbiology · 2026Article
- Pulmonary cryptococcosis with or without immunocompromise: a retrospective comparative study of clinical and CT features and influential factors for lesion absorption.Frontiers in medicine · 2026Article
74 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on byResponse.2020
Authors and funding
46 authors at 20 institutions in 14 countries.
Julio A RamirezDivision of Infectious Diseases, University of Louisville, Louisville, KY. Electronic address: j.ramirez@louisville.edu.
Daniel M MusherBaylor College of Medicine and Michael E. DeBakey VA Medical Center, Houston, TX.
Scott E EvansDepartment of Pulmonary Medicine, University of Texas MD Anderson Cancer Center, Houston, TX.
Charles Dela CruzPulmonary, Critical Care and Sleep Medicine, Yale University, New Haven, CT.
Kristina A CrothersVeterans Puget Sound Health Care System, University of Washington, Seattle WA.
Chadi A HageThoracic Transplant Program, Indiana University, Indianapolis, IN.
Stefano AlibertiDepartment of Pathophysiology and Transplantation, University of Milan, and Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Respiratory Unit and Cystic Fibrosis Adult Center, Milan, Italy.
Antonio AnzuetoSouth Texas Veterans Health Care System, Audie L. Murphy Memorial Veterans Hospital, and University of Texas Health, San Antonio, TX.
Francisco ArancibiaPneumology Service, Instituto Nacional del Tórax and Clínica Santa María, Santiago de Chile, Chile.
Forest ArnoldDivision of Infectious Diseases, University of Louisville, Louisville, KY.
Elie AzoulayMedical ICU, Saint-Louis Teaching Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.
Francesco BlasiDepartment of Pathophysiology and Transplantation, University of Milan, and Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Respiratory Unit and Cystic Fibrosis Adult Center, Milan, Italy.
Jose BordonSection of Infectious Diseases, Providence Health Center, Washington, DC.
Steven BurdetteWright State University Boonshoft School of Medicine, Dayton, OH.
Bin CaoDepartment of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, National Clinical Research Center for Respiratory Diseases, China-Japan Friendship Hospital, Beijing, China.
Rodrigo CavallazziDivision of Pulmonary, Critical Care, and Sleep Disorders Medicine, University of Louisville, Louisville, KY.
James ChalmersScottish Centre for Respiratory Research, School of Medicine, Ninewells Hospital and Medical School, Dundee, UK.
Patrick CharlesDepartment of Infectious Diseases, Austin Health and Department of Medicine, University of Melbourne, Australia.
Jean ChastreService de Médecine Intensive-Réanimation, Hôpital La Pitié-Salpêtrière, Sorbonne Université, APHP, Paris, France.
Yann-Erick ClaessensDepartment of Emergency Medicine, Centre Hospitalier Princesse Grace, Monaco.
Nathan DeanIntermountain Medical Center and the University of Utah, Salt Lake City, UT.
Xavier DuvalUMR 1137, IAME, INSERM, and CIC 1425, Hôpital Bichat-Claude Bernard, APHP, Paris, France.
Muriel FartoukhService de Médecine Intensive Réanimation, Hôpital Tenon, APHP, and APHP, Sorbonne Université, Faculté de Médecine Sorbonne Université, Paris, France.
Charles FeldmanDepartment of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Thomas FileInfectious Disease Section, Northeast Ohio Medical University and Infectious Disease Division, Summa Health, Akron, OH.
Filipe FroesICU, Chest Department, Hospital Pulido Valente-Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.
Stephen FurmanekDivision of Infectious Diseases, University of Louisville, Louisville, KY.
Martin GnoniDivision of Infectious Diseases, University of Louisville, Louisville, KY.
Gustavo LopardoFundación del Centro de Estudios Infectológicos, Buenos Aires, Argentina.
Carlos LunaPulmonary Diseases Division, Universidad de Buenos Aires, Buenos Aires, Argentina.
Takaya MaruyamaDepartment of Respiratory Medicine, National Hospital Organization Mie National Hospital, Tsu, Japan.
Rosario MenendezPneumology Department, La Fe University and Polytechnic Hospital, La Fe Health Research Institute, Valencia, Spain.
Mark MeterskyDivision of Pulmonary, Critical Care and Sleep Medicine and Center for Bronchiectasis Care, University of Connecticut Health, Farmington, CT.
Donna MildvanIcahn School of Medicine at Mount Sinai, New York, NY.
Eric MortensenDepartment of Medicine, University of Connecticut Health Center, Farmington, CT.
Michael S NiedermanPulmonary and Critical Care, New York Presbyterian/Weill Cornell Medical Center and Weill Cornell Medical College, New York, NY.
Mathias PletzInstitute for Infectious Diseases and Infection Control, Jena University Hospital, Jena, Germany.
Jordi RelloCentro de Investigacion Biomedica en Red de Enfermedades Respiratorias, Instituto de Salud Carlos III, and Infections Area, Vall d'Hebron Institute of Research, Barcelona, Spain.
Marcos I RestrepoSouth Texas Veterans Health Care System, Audie L. Murphy Memorial Veterans Hospital, and University of Texas Health, San Antonio, TX.
Yuichiro ShindoDepartment of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Antoni TorresServei de Pneumologia, Hospital Clinic, Universitat de Barcelona. Barcelona, CIBERES, Spain.
Grant WatererSchool of Medicine, University of Western Australia, Perth, Australia.
Brandon WebbDivision of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, UT and Division of Infectious Diseases and Geographic Medicine, Stanford Medicine, Palo Alto, CA.
Tobias WelteGerman Center for Lung Research, Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH) Clinic of Pneumology, Hannover Medical School, Hannover, Germany.
Martin WitzenrathDivision of Pulmonary Inflammation and Department of Infectious Diseases and Respiratory Medicine, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany.
Richard WunderinkPulmonary and Critical Care, Northwestern University Feinberg School of Medicine, Chicago, IL.
University of Louisville · USUConn Health · USUniversity of Milan · ITAssistance Publique – Hôpitaux de Paris · FRAustin Health · AUBaylor College of Medicine · USCentro de Investigación Biomédica en Red de Enfermedades Respiratorias · ESCharité - Universitätsmedizin Berlin · DEChina-Japan Friendship Hospital · CNFundación Centro de Estudios Infectológicos · ARHôpital Saint-Louis · FRHôpital Tenon · FRHospital Pulido Valente · PTHospital Universitari i Politècnic La Fe · ESIcahn School of Medicine at Mount Sinai · USIndiana University – Purdue University Indianapolis · USInstituto Nacional del Tórax · CLIntermountain Medical Center · USJena University Hospital · DEMedizinische Hochschule Hannover · DE
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MTechnology CoreU19AI135964 · NIAID · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LUIS A. Nunes AMARAL · 2018 to 2026
$24.7MNCATS NIH HHS UL1 TR001863NIAID NIH HHS U19 AI135964
Abstract
backgroundCommunity-acquired pneumonia (CAP) guidelines have improved the treatment and outcomes of patients with CAP, primarily by standardization of initial empirical therapy. But current society-published guidelines exclude immunocompromised patients. RESEARCH QUESTION: There is no consensus regarding the initial treatment of immunocompromised patients with suspected CAP. STUDY DESIGN AND
methodsThis consensus document was created by a multidisciplinary panel of 45 physicians with experience in the treatment of CAP in immunocompromised patients. The Delphi survey methodology was used to reach consensus.
resultsThe panel focused on 21 questions addressing initial management strategies. The panel achieved consensus in defining the population, site of care, likely pathogens, microbiologic workup, general principles of empirical therapy, and empirical therapy for specific pathogens.
interpretationThis document offers general suggestions for the initial treatment of the immunocompromised patient who arrives at the hospital with pneumonia.
Indexed as
Community-Acquired InfectionsImmunocompromised HostPatient Care ManagementPneumoniaConsensusHumanscommunity-acquired pneumoniaimmunocompromisedpneumonia
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT06755814ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.